Efficacies of Echinocandins versus Azoles Antifungal agents in Management of Candidaalbicans andCandida dubliniensis

Abstract

Background: Candida infection is a world wide problem with greatly changed epidemiology. Candida dubliniensis is an emerging non-albicans, shares several phenotypic and genotypic characteristics and closely related to Candida albicans. Fluconazole-resistant Candida spp. becomes a significant life-threatening problem especially in high risk patients. Echinocandins are promising antifungals with no recorded resistance. This study was done, first to differentiate C. dubliniensis from C. albicans by different phenotypic and molecular methods and to compare in vitro activities of echinocandins versus azoles against Candida spp.

Antifungal susceptibility, risk factors and treatment outcomes of patients with candidemia at a university hospital in Saudi Arabia

“…Al Thaqafi et al [23] in Saudi Arabia, found that fluconazole-susceptibility was 38.5% for C. albicans and 52.5% for other Candida species, while an Egyptian study of Mohtady et al [28] reported that fluconazole-resistant C. dubliniensis and C. albicans were (55.6%) and (49%), respectively. Omrani et al, [20], found that more than 90% of C.albicans, C. parapsilosis, and C. tropicalis isolates in their study were susceptible to fluconazole and caspofungin.…”